These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8295363

  • 1. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alpha-isopropyl ester analogues for glaucoma treatment.
    Hotehama Y, Mishima HK.
    Jpn J Ophthalmol; 1993; 37(3):259-69. PubMed ID: 8295363
    [Abstract] [Full Text] [Related]

  • 2. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.
    Hotehama Y, Mishima HK, Kitazawa Y, Masuda K.
    Jpn J Ophthalmol; 1993; 37(3):270-4. PubMed ID: 8295364
    [Abstract] [Full Text] [Related]

  • 3. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.
    Bito LZ, Stjernschantz J, Resul B, Miranda OC, Basu S.
    J Lipid Mediat; 1993; 6(1-3):535-43. PubMed ID: 8358014
    [Abstract] [Full Text] [Related]

  • 4. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
    Ziai N, Dolan JW, Kacere RD, Brubaker RF.
    Arch Ophthalmol; 1993 Oct; 111(10):1351-8. PubMed ID: 8216015
    [Abstract] [Full Text] [Related]

  • 5. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens.
    Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J.
    Ophthalmology; 1993 Sep; 100(9):1305-11. PubMed ID: 8371916
    [Abstract] [Full Text] [Related]

  • 6. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE.
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [Abstract] [Full Text] [Related]

  • 7. Effects of prostaglandin D2 and its analogues on intraocular pressure in rabbits.
    Goh Y, Nakajima M, Azuma I, Hayaishi O.
    Jpn J Ophthalmol; 1988 Mar; 32(4):471-80. PubMed ID: 3236567
    [Abstract] [Full Text] [Related]

  • 8. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study.
    Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J.
    Ophthalmology; 1993 Sep; 100(9):1312-6; discussion 1316-7. PubMed ID: 8371917
    [Abstract] [Full Text] [Related]

  • 9. Initial clinical studies with prostaglandins and their analogues.
    Camras CB, Alm A.
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S61-8. PubMed ID: 9154278
    [Abstract] [Full Text] [Related]

  • 10. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
    Toris CB, Camras CB, Yablonski ME.
    Ophthalmology; 1993 Sep; 100(9):1297-304. PubMed ID: 8371915
    [Abstract] [Full Text] [Related]

  • 11. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.
    Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, Bito LZ, Podos SM.
    Arch Ophthalmol; 1992 Dec; 110(12):1733-8. PubMed ID: 1463414
    [Abstract] [Full Text] [Related]

  • 12. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study.
    Rácz P, Ruzsonyi MR, Nagy ZT, Bito LZ.
    Arch Ophthalmol; 1993 May; 111(5):657-61. PubMed ID: 8489449
    [Abstract] [Full Text] [Related]

  • 13. The effects of prostaglandins on the blood-ocular barrier.
    Kosaka T, Mishima HK, Kiuchi Y, Kataoka K.
    Jpn J Ophthalmol; 1995 May; 39(4):368-76. PubMed ID: 8926644
    [Abstract] [Full Text] [Related]

  • 14. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF, Gagliuso DJ, Mittag TW, Podos SM.
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [Abstract] [Full Text] [Related]

  • 15. The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects.
    Lee PY, Shao H, Xu LA, Qu CK.
    Invest Ophthalmol Vis Sci; 1988 Oct; 29(10):1474-7. PubMed ID: 3170119
    [Abstract] [Full Text] [Related]

  • 16. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers.
    Alm A, Villumsen J.
    Arch Ophthalmol; 1991 Nov; 109(11):1564-8. PubMed ID: 1755739
    [Abstract] [Full Text] [Related]

  • 17. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R.
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [Abstract] [Full Text] [Related]

  • 18. Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients.
    Camras CB, Siebold EC, Lustgarten JS, Serle JB, Frisch SC, Podos SM, Bito LZ.
    Ophthalmology; 1989 Sep; 96(9):1329-36; discussion 1336-7. PubMed ID: 2780003
    [Abstract] [Full Text] [Related]

  • 19. Effects of topically applied prostaglandin F2 alpha tromethamine salt on glaucomatous human eyes.
    Erkiliç K, Ekinciler OF, Mirza GE, Doğan H, Cagil N.
    Int J Clin Pharmacol Res; 1996 Sep; 16(2-3):51-5. PubMed ID: 9063756
    [Abstract] [Full Text] [Related]

  • 20. Effects of topically applied PGF2 alpha and its isopropylester on normal and glaucomatous human eyes.
    Alm A, Villumsen J.
    Prog Clin Biol Res; 1989 Sep; 312():447-58. PubMed ID: 2678150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.